+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Infection Drug"

From
Post-surgical Infection - Pipeline Insight, 2024 - Product Thumbnail Image

Post-surgical Infection - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
CNS Bacterial Infections - Pipeline Insight, 2024 - Product Thumbnail Image

CNS Bacterial Infections - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Scedosporium Infection - Pipeline Insight, 2024 - Product Thumbnail Image

Scedosporium Infection - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Eye Infections - Pipeline Insight, 2024 - Product Thumbnail Image

Eye Infections - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Sternal Wound Infection - Pipeline Insight, 2024 - Product Thumbnail Image

Sternal Wound Infection - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Staphylococcus Aureus Infection - Pipeline Insight, 2024 - Product Thumbnail Image

Staphylococcus Aureus Infection - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Surgical Wound Infections - Pipeline Insight, 2024 - Product Thumbnail Image

Surgical Wound Infections - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
Clostridium Difficile Infections - Pipeline Insight, 2024 - Product Thumbnail Image

Clostridium Difficile Infections - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Varicella Zoster (HHV-3) Infections - Pipeline Insight, 2024 - Product Thumbnail Image

Varicella Zoster (HHV-3) Infections - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Hepatitis C Virus Infection - Pipeline Insight, 2024 - Product Thumbnail Image

Hepatitis C Virus Infection - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
From
H1N1 infection - Pipeline Insight, 2024 - Product Thumbnail Image

H1N1 infection - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Chronic Hepatitis C Virus Infection - Pipeline Insight, 2024 - Product Thumbnail Image

Chronic Hepatitis C Virus Infection - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 75 Pages
  • Global
From
From
From
Parainfluenza Virus Infection - Pipeline Insight, 2024 - Product Thumbnail Image

Parainfluenza Virus Infection - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Adenovirus infections - Pipeline Insight, 2024 - Product Thumbnail Image

Adenovirus infections - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Vancomycin resistant Enterococcal infections - Pipeline Insight, 2024 - Product Thumbnail Image

Vancomycin resistant Enterococcal infections - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 40 Pages
  • Global
From
Loading Indicator

The Infectious Diseases Drugs market is a subset of the pharmaceutical industry that focuses on the development and production of drugs used to treat infectious diseases. These drugs are used to treat a wide range of infections, including bacterial, viral, fungal, and parasitic infections. The market is highly competitive, with many companies vying for market share. Companies in the market are typically focused on developing new drugs, as well as improving existing treatments. Additionally, many companies are involved in the production of generic drugs, which are often cheaper than brand-name drugs. Companies in the Infectious Diseases Drugs market include Pfizer, Merck, GlaxoSmithKline, Sanofi, AstraZeneca, Novartis, Johnson & Johnson, and Bristol-Myers Squibb. Show Less Read more